Dechert LLP Advises Selvita on Launch of Nodthera Limited

Dechert LLP advised Selvita S.A., an international drug discovery company with extensive experience in the life sciences sector, on the launch of Nodthera Limited, a new biotech company launched by Epidarex Capital based on research by Selvita. Nodthera Limited, headquartered in Edinburgh, Scotland, will focus on the discovery and development of novel inhibitors of the NLRP3 inflammasome.

The Frankfurt-based Dechert team advising Selvita was led by corporate national partner Jochen Eimer, with assistance from partner Dr. Rüdiger Herrmann and international counsel Alicia Hong.

About Dechert

Dechert is a global specialist law firm focused on sectors with the greatest complexities and highest regulatory demands. We deliver practical commercial insight and judgment to our clients’ most important matters. Nothing stands in the way of giving clients the best of the firm’s entrepreneurial energy and seamless collaboration in a way that is distinctively Dechert.